{"id":"F2012L01731","name":"National Health (Weighted average disclosed price - interim supplementary disclosure cycle) Determination 2012 (No. PB 58 of 2012)","slug":"national-health-weighted-average-disclosed-price-interim-supplementary-disclosure-cycle-determinatio","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":89700,"registerId":"commonwealth-F2012L01731-current","compilationNumber":null,"startDate":"2026-04-02","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Name of Determination \\[see Note 1\\]","content":"1 Name of Determination \\[see Note 1\\]\n\n(1) This Determination is the National Health (Weighted average disclosed price – interim supplementary disclosure cycle) Determination 2012.\n\n(2) This Determination may also be cited as PB 58 of 2012.\n\n","sortOrder":0},{"sectionNumber":"2","sectionType":"section","heading":"Commencement \\[see Note 1\\]","content":"2 Commencement \\[see Note 1\\]\n\nThis Determination commences on the day after it is registered.\n\n","sortOrder":1},{"sectionNumber":"3","sectionType":"section","heading":"Definitions","content":"3 Definitions\n\nIn this Determination:\n\n> Act means the National Health Act 1953.\n\n> adjusted approved ex‑manufacturer price has the same meaning as in subsection 99ADB(1) of the Act.\n\n> adjusted approved price to pharmacists has the same meaning as in subsection 99ADB(1) of the Act.\n\n> interim supplementary disclosure cycle has the same meaning as paragraph 37EB (2) (b), of the National Health (Pharmaceutical Benefits) Regulations 1960.\n\n> unadjusted price reduction has the same meaning as in subsection 99ADB(1) of the Act.\n\n> weighted average disclosed price has the same meaning as in subsection 99ADB(1) of the Act.\n\n","sortOrder":2},{"sectionNumber":"4","sectionType":"section","heading":"Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%","content":"4 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is at least 10%\n\nFor subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 1 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.\n\n","sortOrder":3},{"sectionNumber":"5","sectionType":"section","heading":"Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%","content":"5 Weighted average disclosed price for brands of pharmaceutical items – unadjusted price reduction is less than 10%\n\nFor subsection 99ADB(4) of the Act, the weighted average disclosed price specified in column 3 of an item in Schedule 2 is the weighted average disclosed price for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 2.\n\n","sortOrder":4},{"sectionNumber":"6","sectionType":"section","heading":"Adjusted approved ex‑manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%","content":"6 Adjusted approved ex‑manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%\n\nFor paragraph 99ADB(4) of the Act, the adjusted approved ex‑manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 4 of this instrument.\n\n","sortOrder":5},{"sectionNumber":"7","sectionType":"section","heading":"Adjusted approved price to pharmacists for brands of pharmaceutical items – unadjusted price reduction is at least 10%","content":"7 Adjusted approved price to pharmacists for brands of pharmaceutical items – unadjusted price reduction is at least 10%\n\nFor paragraph 99ADB(4) of the Act, the adjusted approved price to pharmacists specified in column 4 of an item in Schedule 1 is the adjusted approved price to pharmacists for the brand of pharmaceutical item specified in column 2 of the same item in Schedule 1.\n\n","sortOrder":6},{"sectionNumber":"8","sectionType":"section","heading":"Reduction Day","content":"8 Reduction Day\n\nFor paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item in the interim supplementary disclosure cycle with a data collection period ending at the end of 31 May 2012 has a reduction day of 1 December 2012.\n\n","sortOrder":7},{"sectionNumber":"Sch 1","sectionType":"schedule","heading":"Brands of pharmaceutical items – unadjusted price reduction is at least 10%","content":"Schedule 1 Brands of pharmaceutical items – unadjusted price reduction is at least 10%\n\n

Column 1

Column 2

Column 3

Column 4

Item

Brand of Pharmaceutical Item

Weighted average disclosed price

Adjusted approved price to pharmacists

Listed Drug

Form

Manner of administration

Brand

2

Docetaxel

Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent

Injection

Taxotere

267.72

3

Docetaxel

Powder for I.V. infusion 20 mg with solvent

Injection

Docetaxel SUN

66.80

4

Docetaxel

Powder for I.V. infusion 80 mg with solvent

Injection

Docetaxel SUN

267.72

5

Docetaxel

Solution concentrate for I.V. infusion 140 mg in 7 mL

Injection

Oncotaxel 140

466.48

6

Docetaxel

Solution concentrate for I.V. infusion 160 mg in 16 mL

Injection

DBL Docetaxel Concentrated Injection

535.44

7

Docetaxel

Solution concentrate for I.V. infusion 20 mg in 1 mL

Injection

Oncotaxel 20

66.80

8

Docetaxel

Solution concentrate for I.V. infusion 20 mg in 1 mL

Injection

Taxotere

66.80

9

Docetaxel

Solution concentrate for I.V. infusion 20 mg in 2 mL

Injection

DBL Docetaxel Concentrated Injection

66.80

10

Docetaxel

Solution concentrate for I.V. infusion 20 mg in 2 mL

Injection

Docetaxel Ebewe

66.80

11

Docetaxel

Solution concentrate for I.V. infusion 20 mg in 2 mL

Injection

Docetaxel Sandoz

66.80

12

Docetaxel

Solution concentrate for I.V. infusion 80 mg in 4 mL

Injection

Oncotaxel 80

267.72

13

Docetaxel

Solution concentrate for I.V. infusion 80 mg in 4 mL

Injection

Taxotere

267.72

14

Docetaxel

Solution concentrate for I.V. infusion 80 mg in 8 mL

Injection

DBL Docetaxel Concentrated Injection

267.72

15

Docetaxel

Solution concentrate for I.V. infusion 80 mg in 8 mL

Injection

Docetaxel Ebewe

267.72

16

Docetaxel

Solution concentrate for I.V. infusion 80 mg in 8 mL

Injection

Docetaxel Sandoz

267.72

17

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Acpio 15

27.74

29.83

18

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Actos

27.74

29.83

19

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

APOTEX‑Pioglitazone

27.74

29.83

20

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Chem mart Pioglitazone

27.74

29.83

21

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Pharmacor Pioglitazone 15

27.74

29.83

22

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Pioglitazone generichealth 15

27.74

29.83

23

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Pioglitazone Sandoz

27.74

29.83

24

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Pioglitazone‑GA

27.74

29.83

25

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Pizaccord

27.74

29.83

25A

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Prioten 15

27.74

29.83

26

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Terry White Chemists Pioglitazone

27.74

29.83

27

Pioglitazone

Tablet 15 mg (as hydrochloride)

Oral

Vexazone

27.74

29.83

28

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Acpio 30

42.67

45.88

29

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Actos

42.67

45.88

30

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

APOTEX‑Pioglitazone

42.67

45.88

31

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Chem mart Pioglitazone

42.67

45.88

32

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Pharmacor Pioglitazone 30

42.67

45.88

33

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Pioglitazone generichealth 30

42.67

45.88

34

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Pioglitazone Sandoz

42.67

45.88

35

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Pioglitazone‑GA

42.67

45.88

36

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Pizaccord

42.67

45.88

36A

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Prioten 30

42.67

45.88

37

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Terry White Chemists Pioglitazone

42.67

45.88

38

Pioglitazone

Tablet 30 mg (as hydrochloride)

Oral

Vexazone

42.67

45.88

39

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Acpio 45

55.48

59.65

40

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Actos

55.48

59.65

41

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

APOTEX‑Pioglitazone

55.48

59.65

42

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Chem mart Pioglitazone

55.48

59.65

43

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Pharmacor Pioglitazone 45

55.48

59.65

44

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Pioglitazone generichealth 45

55.48

59.65

45

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Pioglitazone Sandoz

55.48

59.65

46

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Pioglitazone‑GA

55.48

59.65

47

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Pizaccord

55.48

59.65

47A

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Prioten 45

55.48

59.65

48

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Terry White Chemists Pioglitazone

55.48

59.65

49

Pioglitazone

Tablet 45 mg (as hydrochloride)

Oral

Vexazone

55.48

59.65

50

Risedronic Acid

Tablet (enteric coated) containing risedronate sodium 35 mg

Oral

Actonel EC

25.49

51

Risedronic Acid

Tablet containing risedronate sodium 150 mg

Oral

Actonel Once-a-Month

27.62

52

Risedronic Acid

Tablet containing risedronate sodium 30 mg

Oral

Actonel

168.36

53

Risedronic Acid

Tablet containing risedronate sodium 35 mg

Oral

Acris Once-a-Week

25.49

54

Risedronic Acid

Tablet containing risedronate sodium 35 mg

Oral

APO-Risedronate

25.49

55

Risedronic Acid

Tablet containing risedronate sodium 35 mg

Oral

Chem mart Risedronate

25.49

56

Risedronic Acid

Tablet containing risedronate sodium 35 mg

Oral

Risedro once a week

25.49

57

Risedronic Acid

Tablet containing risedronate sodium 35 mg

Oral

Risedronate Sandoz

25.49

58

Risedronic Acid

Tablet containing risedronate sodium 35 mg

Oral

Risedronate-GA

25.49

59

Risedronic Acid

Tablet containing risedronate sodium 35 mg

Oral

Terry White Chemists Risedronate

25.49

60

Risedronic Acid

Tablet containing risedronate sodium 5 mg

Oral

Actonel

25.49

\n```\n\n","sortOrder":8},{"sectionNumber":"Sch 2","sectionType":"schedule","heading":"Brands of pharmaceutical items – unadjusted price reduction is less than 10%","content":"Schedule 2 Brands of pharmaceutical items – unadjusted price reduction is less than 10%\n\n

Column 1

Column 2

Column 3

Item

Brand of Pharmaceutical Item

Weighted average disclosed price

Listed Drug

Form

Manner of administration

Brand

1

Perindopril with amlodipine

Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besylate)

Oral

Coveram

27.36

2

Perindopril with amlodipine

Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besylate)

Oral

Reaptan 10/10

27.36

3

Perindopril with amlodipine

Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besylate)

Oral

Coveram

21.45

4

Perindopril with amlodipine

Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besylate)

Oral

Reaptan 10/5

21.45

5

Perindopril with amlodipine

Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besylate)

Oral

Coveram

22.67

6

Perindopril with amlodipine

Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besylate)

Oral

Reaptan 5/10

22.67

7

Perindopril with amlodipine

Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besylate)

Oral

Coveram

16.73

8

Perindopril with amlodipine

Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besylate)

Oral

Reaptan 5/5

16.73

\n```\n\n> Notes to the National Health (Weighted average disclosed price – interim supplementary disclosure cycle) Determination 2012 (PB 58 of 2012)\n\n> Note 1\n\n> Note: The National Health (Weighted average disclosed price – interim supplementary disclosure cycle) Determination 2012 (PB 58 of 2012) (in force under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the National Health Act 1953) as shown in this compilation is amended as indicated in the Tables below.\n\n> Note: > Note: Table of Instruments\n\n| Title | Date of FRLI registration | Date ofcommencement | Application, saving ortransitional provisions |\n| ------------- | ------------------------------ | ------------------- | --------------------------------------------- |\n| PB 58 of 2012 | 22 Aug 2012 (see F2012L01731) | 23 Aug 2012 | |\n| PB 70 of 2012 | 21 Sept 2012 (see F2012L01907) | 22 Sept 2012 | — |\n| PB 98 of 2012 | 5 Nov 2012 (see F2012L02147) | 5 Nov 2012 | — |\n\n> Note: > Note: Table of Amendments\n\n

ad. = added or inserted am. = amended rep. = repealed rs. = repealed and substituted

Provision affected

How affected

Schedule 1

Schedule 1............

am. PB 70 and 98 of 2012

\n```","sortOrder":9}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-realtime","completionTokens":2353},"content_quality":"ok","complexity_score":6,"scope_assessment":{"changed":false,"description":"The Determination maintains its original narrow scope of setting specific prices for the interim supplementary disclosure cycle. Amendments PB 70 and 98 of 2012 updated the specific drug entries in Schedule 1 but did not expand the instrument's purpose beyond price-setting for this specific cycle."},"complexity_factors":["Technical pharmaceutical pricing terminology (weighted average disclosed price, adjusted approved ex-manufacturer price, interim supplementary disclosure cycle)","Cross-references to complex parent legislation (National Health Act 1953, subsection 99ADB(4))","Bifurcated structure separating medicines by price reduction magnitude (10% threshold)","Defined terms imported from Act and Regulations (5 technical definitions)","Tabular schedules with 60+ specific medicine entries requiring precise price specifications"],"plain_english_summary":"This Determination fixes the weighted average disclosed prices the Australian Government will use to subsidise certain PBS medicines, and sets the adjusted approved price pharmacists are paid for those brands. It affects pharmaceutical suppliers, pharmacists and patients by changing government subsidy calculations and out‑of‑pocket costs. Implementing price‑disclosure reforms with a reduction day of 1 December 2012, it brings PBS prices closer to actual market purchase prices and reduces taxpayer medicine subsidy expenses."},"flash_summary":{"complexity_score":4,"scope_assessment":{"changed":true,"description":"The compilation’s Table of Amendments shows Schedule 1 was amended by PB 70 of 2012 and PB 98 of 2012. Those later instruments alter the list of branded items or pricing entries in Schedule 1; accordingly, the set of brands and prices covered by this Determination has been changed from its original form (see Notes: Table of Amendments). No other structural Parts are shown as repealed or substituted in the compilation."},"complexity_factors":["Cross-references to the National Health Act 1953 and the Pharmaceutical Benefits Regulations (subsections 99ADB(1), 99ADB(4) and paragraph 99ADH(1)(aa)) create dependence on external definitions and procedures","Two different legal treatments depending on whether an item’s unadjusted price reduction is at least 10% or less than 10% (ss 4–7, and Schedules 1–2)","Large schedules with many line-item numeric prices and brand identifiers require precise operational matching between legal entries and supply records","Timing/administration element (Reduction Day in s 8) imposes a concrete implementation date","Amendment history (PB 70 and PB 98 of 2012) means the instrument’s scope and entries have been changed since first registration"],"plain_english_summary":"This Determination fixes specific price figures for named branded medicines under the Pharmaceutical Benefits Scheme interim supplementary disclosure cycle. It records weighted average disclosed prices in two schedules, converts those figures into adjusted approved ex‑manufacturer and pharmacist prices for items with at least a 10% unadjusted price reduction (ss 4–7), and sets the Reduction Day for the cycle (s 8). It affects medicine suppliers, pharmacists and government subsidy calculations because those prices determine approved reimbursements and payment timings."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-weighted-average-disclosed-price-interim-supplementary-disclosure-cycle-determinatio","history":"/api/acts/national-health-weighted-average-disclosed-price-interim-supplementary-disclosure-cycle-determinatio/history","analysis":"/api/acts/national-health-weighted-average-disclosed-price-interim-supplementary-disclosure-cycle-determinatio/analysis","conflicts":"/api/acts/national-health-weighted-average-disclosed-price-interim-supplementary-disclosure-cycle-determinatio/conflicts","importantCases":"/api/acts/national-health-weighted-average-disclosed-price-interim-supplementary-disclosure-cycle-determinatio/important-cases","documents":"/api/acts/national-health-weighted-average-disclosed-price-interim-supplementary-disclosure-cycle-determinatio/documents"}}